- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04039607
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (CheckMate 9DW)
January 17, 2024 updated by: Bristol-Myers Squibb
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
732
Phase
- Phase 3
Expanded Access
Approved for sale to the public.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tucuman, Argentina, 4000
- Local Institution - 0058
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, 1426
- Local Institution - 0136
-
Caba, Buenos Aires, Argentina, C1090AAS
- Local Institution - 0037
-
Pilar, Buenos Aires, Argentina, B1629AHJ
- Local Institution - 0194
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, 2000
- Local Institution - 0282
-
-
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Local Institution - 0003
-
Liverpool, New South Wales, Australia, 1871
- Local Institution - 0038
-
Westmead, New South Wales, Australia, 2145
- Local Institution - 0002
-
-
Queensland
-
Birtinya, Queensland, Australia, 4560
- Local Institution - 0004
-
Herston, Queensland, Australia, 4029
- Local Institution - 0013
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Local Institution - 0009
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Local Institution - 0019
-
Fitzroy, Victoria, Australia, 3065
- Local Institution - 0026
-
Melbourne, Victoria, Australia, 3004
- Local Institution - 0001
-
St Albans, Victoria, Australia, 3021
- Local Institution - 0020
-
-
-
-
-
Graz, Austria, 8036
- Local Institution - 0188
-
Klagenfurt, Austria, 9020
- Local Institution - 0065
-
St. Polten, Austria, 3100
- Local Institution - 0114
-
Viena, Austria, 1090
- Local Institution - 0186
-
-
Niederosterreich
-
Wiener Neustadt, Niederosterreich, Austria, 2700
- Local Institution - 0057
-
-
-
-
-
Federal District, Belgium, 72115700
- Local Institution - 0008
-
Gent, Belgium, 9000
- Local Institution - 0298
-
Gent, Belgium, 9000
- Local Institution - 0124
-
Haine-Saint-Paul, Belgium, 7100
- Local Institution - 0099
-
Leuven, Belgium, 3000
- Local Institution - 0034
-
Leuven, Belgium, 3000
- Local Institution - 0064
-
Liege, Belgium, 4000
- Local Institution - 0104
-
-
-
-
-
Rio de Janeiro, Brazil, 22793-080
- Local Institution - 0015
-
Sao Paulo, Brazil, 01246-000
- Local Institution - 0023
-
Sao Paulo, Brazil, 01323-001
- Local Institution - 0022
-
Sao Paulo, Brazil, 04038-034
- Local Institution - 0050
-
-
Bahia
-
Salvador, Bahia, Brazil, 41253190
- Local Institution
-
Salvador, Bahia, Brazil, 41950-640
- Local Institution - 0061
-
-
DF
-
Brasilia, DF, Brazil, 70200-730
- Local Institution - 0181
-
-
Espirito Santo
-
Vitoria, Espirito Santo, Brazil, 29055-450
- Local Institution - 0278
-
-
Parana
-
Curitiba, Parana, Brazil, 81520060
- Local Institution - 0016
-
-
RIO Grande DO SUL
-
Pelotas, RIO Grande DO SUL, Brazil, 960400-10
- Local Institution - 0060
-
-
Rio Grande Do Sul
-
Ijui, Rio Grande Do Sul, Brazil, 98700-000
- Local Institution - 0279
-
-
SAO Paulo
-
Jau, SAO Paulo, Brazil, 17210-120
- Local Institution - 0054
-
-
Sao Paulo
-
Sao Jose do Rio Preto, Sao Paulo, Brazil, 15090-000
- Local Institution - 0280
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Local Institution - 0192
-
-
-
-
Araucania
-
Temuco, Araucania, Chile, 4780000
- Local Institution - 0296
-
-
Coquimbo
-
La Serena, Coquimbo, Chile, 1720430
- Local Institution - 0094
-
-
Metropolitana
-
Santiago, Metropolitana, Chile, 7620002
- Local Institution - 0024
-
Santiago, Metropolitana, Chile, 8380456
- Local Institution - 0156
-
Santiago de Chile, Metropolitana, Chile
- Local Institution - 0095
-
-
RM
-
Santiago, RM, Chile, 7630372
- Local Institution - 0283
-
-
Valparaiso
-
Vina del Mar, Valparaiso, Chile, 2540402
- Local Institution - 0216
-
Vina del Mar, Valparaiso, Chile, 2520598
- Local Institution - 0012
-
-
-
-
-
Xi'an, China, 710126
- Local Institution - 0307
-
-
Anhui
-
Hefei, Anhui, China, 230065
- Local Institution - 0146
-
Hefei Shi, Anhui, China, 230022
- Local Institution - 0120
-
-
Beijing
-
Beijing, Beijing, China, 100089
- Local Institution - 0175
-
Beijing, Beijing, China, 100853
- Local Institution - 0152
-
-
Fujian
-
Fuzhou, Fujian, China, 350002
- Local Institution - 0151
-
Fuzhou City, Fujian, China, 350014
- Local Institution - 0121
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Local Institution - 0125
-
Guangzhou, Guangdong, China, 510515
- Local Institution - 0150
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Local Institution - 0135
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Local Institution - 0059
-
Changsha, Hunan, China, 410006
- Local Institution - 0109
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Local Institution - 0130
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Local Institution - 0145
-
Nanchang, Jiangxi, China, 330019
- Local Institution - 0149
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Local Institution - 0162
-
Changchun, Jilin, China, 130102
- Local Institution - 0166
-
-
Liaoning
-
Dalian, Liaoning, China, 116023
- Local Institution - 0131
-
Shenyang, Liaoning, China, 110004
- Local Institution - 0123
-
Shenyang, Liaoning, China, 110117
- Local Institution - 0132
-
-
Shaanxi
-
Xian, Shaanxi, China, 710061
- Local Institution - 0147
-
-
Shan3xi
-
Xian, Shan3xi, China, 710038
- Local Institution - 0133
-
-
Shandong
-
Qingdao, Shandong, China, 266000
- Local Institution - 0153
-
-
Shanghai
-
Shanghai, Shanghai, China, 201315
- Local Institution - 0134
-
-
Sichuan
-
Chongqing, Sichuan, China, 400030
- Local Institution - 0179
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310022
- Local Institution - 0107
-
Hangzhou, Zhejiang, China, 310000
- Local Institution - 0108
-
-
-
-
-
Brno, Czechia, 60200
- Local Institution
-
-
Prague
-
Praha, Prague, Czechia, 14059
- Local Institution - 0274
-
-
-
-
-
Amiens, France, 80054
- Local Institution - 0068
-
Caen, France, 14033
- Local Institution - 0116
-
Clichy, France, 92110
- Local Institution - 0069
-
Dijon, France, 21000
- Local Institution - 0138
-
Grenoble Cedex 9, France, 38043
- Local Institution - 0081
-
Lyon, France, 69004
- Local Institution - 0070
-
Marseille, France, 13009
- Local Institution
-
Montpellier, France, 34295
- Local Institution - 0082
-
Nice, France, 6202
- Local Institution - 0067
-
Pessac, France, 33604
- Local Institution - 0025
-
Poitiers, France, 86021
- Local Institution - 0137
-
Toulouse Cedex 9, France, 31059
- Local Institution - 0042
-
Vandoeuvre les Nancy, France, 54500
- Local Institution - 0071
-
Villejuif, France, 94800
- Local Institution - 0051
-
-
-
-
-
Bonn, Germany, 53127
- Local Institution - 0231
-
Essen, Germany, 45147
- Local Institution - 0052
-
Freiburg, Germany, 79106
- Local Institution - 0185
-
Hamburg, Germany, 20246
- Local Institution - 0006
-
Hannover, Germany, 30625
- Local Institution - 0102
-
Koeln, Germany, 50937
- Local Institution - 0028
-
Leipzig, Germany, 04103
- Local Institution - 0118
-
Mainz, Germany, 55131
- Local Institution - 0031
-
Mannheim, Germany, 68167
- Local Institution - 0056
-
Munchen, Germany, 81675
- Local Institution
-
North Rhine-Westphalia, Germany, 45136
- Local Institution - 0053
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- Local Institution - 0005
-
-
-
-
-
Hong Kong, Hong Kong
- Local Institution - 0032
-
Hong Kong, Hong Kong, 999077
- Local Institution - 0036
-
-
-
-
-
Candiolo, Italy, 10060
- Local Institution - 0084
-
Milano, Italy, 20122
- Local Institution - 0039
-
Novara, Italy, 28100
- Local Institution - 0100
-
Padova, Italy, 35128
- Local Institution - 0219
-
Parma, Italy, 43126
- Local Institution - 0033
-
Roma, Italy, 00128
- Local Institution - 0112
-
Rome, Italy, 00168
- Local Institution - 0079
-
Siena, Italy, 53100
- Local Institution - 0111
-
Vicenza, Italy, 36100
- Local Institution - 0044
-
-
Forli-Cesena
-
Meldola, Forli-Cesena, Italy, 47014
- Local Institution - 0110
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Local Institution - 0101
-
-
-
-
-
Fukuoka, Japan, 830-0011
- Local Institution - 0178
-
Hiroshima, Japan, 7348551
- Local Institution - 0177
-
Kanagawa, Japan, 213-8587
- Local Institution - 0122
-
Saitama, Japan, 350-0495
- Local Institution - 0258
-
-
Chiba
-
Chiba-shi, Chiba, Japan, 2608677
- Local Institution - 0204
-
Kashiwa-shi, Chiba, Japan, 2778577
- Local Institution - 0193
-
-
Ehime
-
Matsuyama, Ehime, Japan, 790-0024
- Local Institution - 0203
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan, 060-0033
- Local Institution - 0155
-
-
Ishikawa
-
Kanazawa, Ishikawa, Japan, 920-8641
- Local Institution - 0176
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 241-8515
- Local Institution - 0262
-
Yokohama-Shi, Kanagawa, Japan, 232-0024
- Local Institution - 0200
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan, 602-8566
- Local Institution - 0189
-
-
Nara
-
Kashihara City, Nara, Japan, 634-8522
- Local Institution - 0261
-
-
Osaka
-
Abeno-ku, Osaka, Japan, 5458586
- Local Institution - 0263
-
Osakasayama, Osaka, Japan, 5898511
- Local Institution - 0127
-
-
Saga
-
Saga Shi, Saga, Japan, 8408571
- Local Institution - 0281
-
-
Shizuoka
-
Izunokuni-shi, Shizuoka, Japan, 4102295
- Local Institution - 0259
-
-
Tokyo
-
Minato-ku, Tokyo, Japan, 1058470
- Local Institution - 0128
-
Mitaka, Tokyo, Japan, 181-8611
- Local Institution - 0201
-
Musashino-shi, Tokyo, Japan, 180-8610
- Local Institution - 0199
-
-
-
-
-
Busan, Korea, Republic of, 049241
- Local Institution - 0142
-
Gyeonggi-do, Korea, Republic of, 010408
- Local Institution - 0097
-
Gyeongsangnam-do, Korea, Republic of, 050612
- Local Institution - 0098
-
Seoul, Korea, Republic of, 03722
- Local Institution - 0141
-
Seoul, Korea, Republic of, 05505
- Local Institution - 0140
-
Seoul, Korea, Republic of, 06351
- Local Institution - 0139
-
Seoul, Korea, Republic of, 08308
- Local Institution - 0167
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13496
- Local Institution - 0143
-
-
Seoul
-
Jongno-gu, Seoul, Korea, Republic of, 03080
- Local Institution - 0062
-
-
-
-
-
Auckland, New Zealand, 1142
- Local Institution - 0047
-
-
-
-
-
Gdansk, Poland, 80219
- Local Institution - 0148
-
Otwock, Poland, 05-400
- Local Institution - 0049
-
Warszawa, Poland, 02-034
- Local Institution - 0092
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Local Institution - 0289
-
San Juan, Puerto Rico, 00927-4308
- Local Institution - 0035
-
-
-
-
-
Bucharest, Romania, 022328
- Local Institution - 0164
-
Cluj Napoca, Romania, 400015
- Local Institution - 0165
-
Craiova, Romania, 200385
- Local Institution
-
Timisoara, Romania, 300166
- Local Institution - 0163
-
-
Dolj
-
Craiova, Dolj, Romania, 200542
- Local Institution - 0103
-
-
-
-
-
Arkhangelsk, Russian Federation, 163045
- Local Institution - 0029
-
Barnaul, Russian Federation, 656045
- Local Institution - 0066
-
Chelyabinsk, Russian Federation, 454087
- Local Institution - 0074
-
Moscow, Russian Federation, 115478
- Local Institution - 0007
-
Pyatigorsk, Russian Federation, 357502
- Local Institution - 0072
-
Saint-Petersburg, Russian Federation, 197758
- Local Institution - 0075
-
Saint-Petersburg, Russian Federation, 198255
- Local Institution - 0091
-
Sochi, Russian Federation, 354057
- Local Institution - 0073
-
-
-
-
-
Singapore, Singapore, 258499
- Local Institution - 0017
-
Singapore, Singapore, 308442
- Local Institution - 0174
-
Singapore, Singapore, 168583
- Local Institution - 0048
-
-
-
-
-
Barcelona, Spain, 08035
- Local Institution - 0297
-
Barcelona, Spain, 08036
- Local Institution - 0055
-
Barcelona, Spain, 08908
- Local Institution - 0089
-
Cordoba, Spain, 14004
- Local Institution - 0090
-
El Palmar, Spain, 30120
- Local Institution - 0087
-
Madrid, Spain, 28007
- Local Institution - 0041
-
Madrid, Spain, 28028
- Local Institution - 0093
-
Madrid, Spain, 28035
- Local Institution - 0290
-
Majadahonda, Spain, 28222
- Local Institution - 0045
-
Pamplona, Spain, 31008
- Local Institution - 0085
-
Santander, Spain, 39008
- Local Institution - 0088
-
Zaragoza, Spain, 50009
- Local Institution - 0040
-
-
-
-
-
Bern, Switzerland, 3010
- Local Institution - 0063
-
-
-
-
-
Kaohsiung, Taiwan, 807
- Local Institution - 0272
-
Kaohsiung, Taiwan, 83301
- Local Institution - 0096
-
Taichung, Taiwan, 40447
- Local Institution - 0105
-
Taichung, Taiwan, 40705
- Local Institution - 0271
-
Tainan, Taiwan, 704
- Local Institution - 0168
-
Tainan, Taiwan, 736
- Local Institution - 0270
-
Taipei, Taiwan, 100
- Local Institution - 0144
-
Taoyuan, Taiwan, 333
- Local Institution - 0173
-
Tapei, Taiwan, 11217
- Local Institution - 0078
-
-
-
-
-
Christchurch, United Kingdom, BH23 2JX
- Local Institution - 0286
-
Edinburgh, United Kingdom, EH4 2XU
- Local Institution - 0160
-
London, United Kingdom, SE5 9RS
- Local Institution - 0129
-
-
Greater London
-
London, Greater London, United Kingdom, W12 OHS
- Local Institution - 0171
-
-
Surrey
-
Guildford, Surrey, United Kingdom, GU2 7XX
- Local Institution - 0154
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85719
- Local Institution - 0292
-
-
California
-
Coronado, California, United States, 92118
- Local Institution - 0288
-
Duarte, California, United States, 91010-3012
- Local Institution - 0157
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Local Institution - 0077
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Local Institution - 0027
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Local Institution - 0190
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Local Institution
-
Detroit, Michigan, United States, 48202
- Local Institution - 0018
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- Local Institution - 0295
-
-
Ohio
-
Toledo, Ohio, United States, 43623
- Local Institution - 0043
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Local Institution - 0284
-
-
Texas
-
Dallas, Texas, United States, 75203
- Local Institution - 0304
-
Houston, Texas, United States, 77030
- Local Institution - 0202
-
Lubbock, Texas, United States, 79410
- Local Institution - 0046
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Local Institution - 0172
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants must have a diagnosis of HCC based on histological confirmation
- Participants must have an advanced HCC
- Participants must have at least one Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable previously untreated lesion
- Child-Pugh score 5 or 6
- Eastern Cooperative Oncology Group (ECOG) performance status(PS) 0 or 1
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior liver transplant
- Episodes of hepatic encephalopathy (greater than or equal to [>=] Grade 2) within 12 months prior to randomization
- Active brain metastases or leptomeningeal metastases
Other protocol-defined inclusion/exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nivolumab + Ipilimumab
|
Participants will receive nivolumab as intravenous (IV) infusion.
Participants will receive ipilimumab as IV infusion.
|
Active Comparator: Sorafenib/lenvatinib
|
Participants will receive sorafenib as oral tablets.
Participants will receive lenvatinib as oral capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival (OS)
Time Frame: Up to 4 years
|
Up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of Response (DOR)
Time Frame: Up to 4 years
|
Up to 4 years
|
Objective Response Rate (ORR)
Time Frame: Up to 4 years
|
Up to 4 years
|
Time to Symptom Deterioration (TTSD)
Time Frame: Up to 4 years
|
Up to 4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2019
Primary Completion (Estimated)
July 6, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
July 30, 2019
First Submitted That Met QC Criteria
July 30, 2019
First Posted (Actual)
July 31, 2019
Study Record Updates
Last Update Posted (Actual)
January 18, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Sorafenib
- Nivolumab
- Lenvatinib
- Ipilimumab
Other Study ID Numbers
- CA209-9DW
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on Nivolumab
-
Universitair Ziekenhuis BrusselNot yet recruiting
-
Brown UniversityBristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...Terminated
-
Bristol-Myers SquibbRecruitingMelanomaSpain, United States, Italy, Chile, Greece, Argentina
-
Baptist Health South FloridaBristol-Myers Squibb; NovoCure Ltd.TerminatedRecurrent GlioblastomaUnited States
-
Jason J. Luke, MDArray BioPharmaActive, not recruitingMelanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Michael B. Atkins, MDBristol-Myers Squibb; Hoosier Cancer Research NetworkActive, not recruitingAdvanced Renal Cell CarcinomaUnited States
-
Bristol-Myers SquibbCompletedLung CancerItaly, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
-
IRCCS San RaffaeleBristol-Myers SquibbRecruiting
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsRecruitingHepatocellular Carcinoma (HCC)Taiwan